ClinicalTrials.Veeva

Menu

Lipid Management in Clinical Practice (MK-0524A-115)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status

Completed

Conditions

Lipid Metabolism Disorder

Study type

Observational

Funder types

Industry

Identifiers

NCT01071278
2010_011 (Other Identifier)
0524A-115

Details and patient eligibility

About

The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.

Enrollment

2,390 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients are 18 years of age or older with lipid disorder treated with nicotinic acid/laropiprant

Exclusion criteria

  • Patient is currently participating in a clinical trial

Trial design

2,390 participants in 2 patient groups

Patients treated within a disease management program
Description:
Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
Patients treated outside a disease management program
Description:
Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems